Is the large simple trial design used for comparative, post-approval safety research? A review of a clinical trials registry and the published literature
| Autor: | Robert F. Reynolds, Sybil M. Eng, Nicolle M. Gatto, Joanna Lem |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Research design
medicine.medical_specialty Biomedical Research Drug-Related Side Effects and Adverse Reactions Psychological intervention MEDLINE Toxicology Product Surveillance Postmarketing Medicine Humans Pharmacology (medical) Medical physics Registries Drug Approval Pharmacology Publishing Clinical Trials as Topic Data collection business.industry Confounding Clinical trial Sample size determination Research Design Sample Size Observational study business |
| Zdroj: | Drug safety. 34(10) |
| ISSN: | 1179-1942 |
| Popis: | Post-approval, observational drug safety studies face well known difficulties in controlling for confounding, particularly confounding by indication for drug use. A study design that addresses confounding by indication is the large simple trial (LST). LSTs are characterized by large sample sizes, often in the thousands; broad entry criteria consistent with the approved medication label; randomization based on equipoise, i.e. neither physician nor patient believes that one treatment option is superior; minimal, streamlined data collection requirements; objectively-measured endpoints (e.g. death, hospitalization); and follow-up that minimizes interventions or interference with normal clinical practice. In theory then, the LST is a preferred study design for drug and vaccine safety research because it controls for biases inherent to observational research while still providing results that are generalizable to 'real-world' use. To evaluate whether LSTs are used for comparative safety evaluation and if the design is, in fact, advantageous compared with other designs, we conducted a review of the published literature (1949 through 31 December 2010) and the ClinicalTrials.gov registry (2000 through 31 December 2010). Thirteen ongoing or completed safety LSTs were identified. The design has rarely been used in comparative drug safety research, which is due to the operational, financial and scientific hurdles of implementing the design. The studies that have been completed addressed important clinical questions and, in some cases, led to re-evaluation of medical practice. We conclude the design has demonstrated utility for comparative safety research of medicines and vaccines if the necessary scientific and operational conditions for its use are met. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink